Suppr超能文献

相似文献

1
Physiological phenotype and vulnerability in Parkinson's disease.
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a009290. doi: 10.1101/cshperspect.a009290.
2
Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease.
J Biol Chem. 2013 Apr 12;288(15):10736-41. doi: 10.1074/jbc.R112.410530. Epub 2012 Oct 19.
3
What causes the death of dopaminergic neurons in Parkinson's disease?
Prog Brain Res. 2010;183:59-77. doi: 10.1016/S0079-6123(10)83004-3.
4
The origins of oxidant stress in Parkinson's disease and therapeutic strategies.
Antioxid Redox Signal. 2011 Apr 1;14(7):1289-301. doi: 10.1089/ars.2010.3521. Epub 2010 Dec 15.
6
The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Gene. 2013 Dec 10;532(1):18-23. doi: 10.1016/j.gene.2013.07.085. Epub 2013 Aug 15.
7
The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.
Neuroscience. 2011 Dec 15;198:221-31. doi: 10.1016/j.neuroscience.2011.08.045. Epub 2011 Aug 25.
8
Parkinson's disease: return of an old prime suspect.
Neuron. 2007 Jul 5;55(1):8-10. doi: 10.1016/j.neuron.2007.06.023.
9
Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.
Cell Calcium. 2010 Feb;47(2):175-82. doi: 10.1016/j.ceca.2009.12.003. Epub 2010 Jan 6.
10
Pathogenesis and animal studies of Parkinson's disease.
Curr Opin Neurol Neurosurg. 1993 Jun;6(3):323-32.

引用本文的文献

2
Levodopa treatment: impacts and mechanisms throughout Parkinson's disease progression.
J Neural Transm (Vienna). 2025 Apr 11. doi: 10.1007/s00702-025-02893-4.
4
Calcium Ions in the Physiology and Pathology of the Central Nervous System.
Int J Mol Sci. 2024 Dec 6;25(23):13133. doi: 10.3390/ijms252313133.
5
Modulating the cholinergic system-Novel targets for deep brain stimulation in Parkinson's disease.
J Neurochem. 2025 Feb;169(2):e16264. doi: 10.1111/jnc.16264. Epub 2024 Nov 18.
7
Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology.
Neurotoxicology. 2024 Jul;103:266-287. doi: 10.1016/j.neuro.2024.06.016. Epub 2024 Jul 2.
8
The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.
Int J Mol Sci. 2024 Apr 15;25(8):4358. doi: 10.3390/ijms25084358.
9
Somatodendritic organization of pacemaker activity in midbrain dopamine neurons.
Korean J Physiol Pharmacol. 2024 Mar 1;28(2):165-181. doi: 10.4196/kjpp.2024.28.2.165.
10
Mitochondrial dysfunction in Parkinson's disease - a key disease hallmark with therapeutic potential.
Mol Neurodegener. 2023 Nov 11;18(1):83. doi: 10.1186/s13024-023-00676-7.

本文引用的文献

1
Mitochondrial pathology in Parkinson's disease.
Mt Sinai J Med. 2011 Nov-Dec;78(6):872-81. doi: 10.1002/msj.20303.
3
Pathological roles of α-synuclein in neurological disorders.
Lancet Neurol. 2011 Nov;10(11):1015-25. doi: 10.1016/S1474-4422(11)70213-7.
4
Thioredoxin 1 overexpression extends mainly the earlier part of life span in mice.
J Gerontol A Biol Sci Med Sci. 2011 Dec;66(12):1286-99. doi: 10.1093/gerona/glr125. Epub 2011 Aug 26.
5
Mitochondrial dysfunction in genetic animal models of Parkinson's disease.
Antioxid Redox Signal. 2012 May 1;16(9):896-919. doi: 10.1089/ars.2011.4200. Epub 2011 Oct 4.
6
Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis.
Cold Spring Harb Perspect Biol. 2011 Oct 1;3(10):a007500. doi: 10.1101/cshperspect.a007500.
8
A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter.
Nature. 2011 Jun 19;476(7360):336-40. doi: 10.1038/nature10230.
9
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
Neurobiol Dis. 2011 Aug;43(2):364-71. doi: 10.1016/j.nbd.2011.04.007. Epub 2011 Apr 16.
10
Modulation of striatal projection systems by dopamine.
Annu Rev Neurosci. 2011;34:441-66. doi: 10.1146/annurev-neuro-061010-113641.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验